List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6944571/publications.pdf Version: 2024-02-01



FRICE MORAND

#	Article	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
2	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care and Research, 2022, 74, 2033-2041.	3.4	6
3	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clinical Rheumatology, 2022, 41, 357-366.	2.2	10
4	Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 1900-1910.	1.9	10
5	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. Rheumatology, 2022, 61, 1341-1353.	1.9	4
6	Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?. Lancet Rheumatology, The, 2022, , .	3.9	4
7	Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia. Cells, 2022, 11, 532.	4.1	4
8	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern Rheumatology, 2022, , .	1.8	3
9	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatology, The, 2022, 4, e282-e292.	3.9	34
10	Easy-BILAC: as easy as ABC?. Rheumatology, 2022, 61, 3879-3880.	1.9	1
11	Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Science and Medicine, 2022, 9, e000625.	2.7	24
12	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatology, The, 2022 4 e198-e207	3.9	7
13	â€~Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	3.5	17
14	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
15	The Relationship between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. Journal of Clinical Pharmacology, 2022, , .	2.0	1
16	Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 4752-4762.	1.9	15
17	Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology, 2022, 62, 190-199.	1.9	7
18	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17

#	Article	IF	CITATIONS
19	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.9	15
20	Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation. Immunology and Cell Biology, 2022, 100, 605-623.	2.3	1
21	Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study. Arthritis Research and Therapy, 2022, 24, .	3.5	Ο
22	GILZ regulates type I interferon release and sequesters STAT1. Journal of Autoimmunity, 2022, 131, 102858.	6.5	5
23	Breaking the chain of transmission within a tertiary health service: An approach to contact tracing during the COVID-19 pandemic. Infection, Disease and Health, 2021, 26, 118-122.	1.1	8
24	Algorithm for calculating high disease activity in SLE. Rheumatology, 2021, 60, 4291-4297.	1.9	11
25	Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention. Lupus, 2021, 30, 687-688.	1.6	1
26	Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Science and Medicine, 2021, 8, e000464.	2.7	45
27	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	2.7	7
28	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology, 2021, 60, 5379-5389.	1.9	11
29	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational <i>study</i> . Rheumatology, 2021, 60, 5185-5193.	1.9	9
30	The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit. Rheumatology, 2021, 60, 3478-3480.	1.9	12
31	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	3.9	26
32	Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatology, The, 2021, 3, e168-e170.	3.9	24
33	What Does it Mean to be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. Arthritis and Rheumatology, 2021, 73, 2059-2068.	5.6	12
34	GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus. Frontiers in Immunology, 2021, 12, 652800.	4.8	7
35	Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′- <i>O</i> -methyl gapmer oligonucleotides. Nucleic Acids Research, 2021, 49, 6082-6099.	14.5	16
36	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus, 2021, 30, 1254-1263.	1.6	36

#	Article	IF	CITATIONS
37	POS0688â€CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE. Annals of the Rheumatic Diseases, 2021, 80, 590-591.	0.9	3
38	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Science and Medicine, 2021, 8, e000506.	2.7	1
39	OP0296â€THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE. Annals of the Rheumatic Diseases, 2021, 80, 181.1-182.	0.9	10
40	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. International Journal of Rheumatic Diseases, 2021, 24, 880-895.	1.9	11
41	Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. Lancet Rheumatology, The, 2021, 3, e357-e370.	3.9	14
42	Impact of <scp>COVID</scp> â€19 telehealth on outpatient test completion. Internal Medicine Journal, 2021, 51, 1614-1618.	0.8	1
43	Treatment Update in Systemic Lupus Erythematous. Rheumatic Disease Clinics of North America, 2021, 47, 513-530.	1.9	6
44	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. Rheumatic Disease Clinics of North America, 2021, 47, 415-426.	1.9	4
45	Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study. Lupus, 2021, 30, 1586-1595.	1.6	1
46	Disease course following High Disease Activity Status revealed patterns in SLE. Arthritis Research and Therapy, 2021, 23, 191.	3.5	3
47	Systemic lupus erythematosus: a clinical update. Internal Medicine Journal, 2021, 51, 1219-1228.	0.8	2
48	SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. Human Vaccines and Immunotherapeutics, 2021, 17, 4048-4056.	3.3	25
49	Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatology, The, 2021, 3, e595-e603.	3.9	13
50	Severe infections remain common in a real-world rheumatoid arthritis cohort: A simple clinical model to predict infection risk. , 2021, 8, 133-138.		5
51	Glucocorticoids. , 2021, , 611-622.		0
52	Filgotinib in cutaneous lupus: is a negative positive?. Rheumatology, 2021, , .	1.9	0
53	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
54	Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE. Lupus Science and Medicine, 2021, 8, e000580.	2.7	8

#	Article	IF	CITATIONS
55	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
56	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 1289-1295.	3.4	19
57	Plasmacytoid dendritic cells from parent strains of the NZB/W F1 lupus mouse contribute different characteristics to autoimmune propensity. Immunology and Cell Biology, 2020, 98, 203-214.	2.3	1
58	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
59	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatology, The, 2020, 2, e24-e30.	3.9	45
60	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. Cell Reports, 2020, 33, 108290.	6.4	4
61	Utility of repeated antinuclear antibody tests: a retrospective database study. Lancet Rheumatology, The, 2020, 2, e412-e417.	3.9	15
62	Necrotic cell death increases the release of macrophage migration inhibitory factor by monocytes/macrophages. Immunology and Cell Biology, 2020, 98, 782-790.	2.3	13
63	Associations of metabolic syndrome in SLE. Lupus Science and Medicine, 2020, 7, e000436.	2.7	14
64	Interferon blockade in systemic lupus erythematosus: Light at the end of the tunnel for novel therapies for lupus?. International Journal of Rheumatic Diseases, 2020, 23, 995-997.	1.9	0
65	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	1.9	12
66	Establishing Consensus Understanding of the Barriers to Drug Development in Lupus. Therapeutic Innovation and Regulatory Science, 2020, 54, 1159-1165.	1.6	2
67	Glucocorticoid-induced leucine zipper modulates macrophage polarization and apoptotic cell clearance. Pharmacological Research, 2020, 158, 104842.	7.1	22
68	Response to: â€~Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?' by Chessa et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217692.	0.9	0
69	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Science and Medicine, 2020, 7, e000372.	2.7	23
70	Perspectives of Patients With Rheumatic Diseases in the Early Phase of <scp>COVID</scp> â€19. Arthritis Care and Research, 2020, 72, 1189-1195.	3.4	37
71	Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Science and Medicine, 2020, 7, e000375.	2.7	15
72	Connexin-Dependent Transfer of cGAMP to Phagocytes Modulates Antiviral Responses. MBio, 2020, 11, .	4.1	44

#	Article	IF	CITATIONS
73	Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Internal Medicine Journal, 2020, 50, 374-377.	0.8	10
74	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	1.9	33
75	Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. Arthritis Research and Therapy, 2020, 22, 8.	3.5	32
76	Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE. Annals of the Rheumatic Diseases, 2020, 79, 787-792.	0.9	20
77	Assays for Inducing and Measuring Cell Death to Detect Macrophage Migration Inhibitory Factor (MIF) Release. Methods in Molecular Biology, 2020, 2080, 173-183.	0.9	2
78	OP0049â€EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS. Annals of the Rheumatic Diseases, 2020, 79, 32-32.	0.9	9
79	Response to: â€~Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zenet al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217687.	0.9	0
80	AB0376â€DETERMINANTS AND PROTECTIVE EFFECTS OF A LOW DISEASE ACTIVITY STATE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PROSPECTIVE CHINESE COHORT. Annals of the Rheumatic Diseases, 2020, 79, 1488-1489.	0.9	0
81	Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren's syndrome. Joint Bone Spine, 2019, 86, 393-395.	1.6	4
82	Effect of storage duration on cytokine stability in human serum and plasma. Cytokine, 2019, 113, 453-457.	3.2	23
83	Outcomes of patients admitted to hospital medical units with back pain. Internal Medicine Journal, 2019, 49, 316-322.	0.8	16
84	Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2019, 10, 1649.	4.8	4
85	Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?. Frontiers in Immunology, 2019, 10, 1684.	4.8	17
86	Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?. Journal of Rheumatology, 2019, 46, 1256-1258.	2.0	6
87	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatology, The, 2019, 1, e103-e110.	3.9	38
88	Defining remission in systemic lupus erythematosus: still elusive?. Lancet Rheumatology, The, 2019, 1, e137-e138.	3.9	0
89	Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus. Scientific Reports, 2019, 9, 15433.	3.3	16
90	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	3.9	250

#	Article	IF	CITATIONS
91	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatology, The, 2019, 1, e95-e102.	3.9	65
92	Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity. Nature Medicine, 2019, 25, 1428-1441.	30.7	185
93	Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 629-633.	0.9	53
94	Analysis of serum interleukin(<scp>IL</scp>)â€lα, <scp>IL</scp> â€lβ and <scp>IL</scp> â€l8 in patients with systemic sclerosis. Clinical and Translational Immunology, 2019, 8, e1045.	3.8	16
95	Analysis of serum B cellâ€activating factor from the tumor necrosis factor family (<scp>BAFF</scp>) and its soluble receptors in systemic lupus erythematosus. Clinical and Translational Immunology, 2019, 8, e01047.	3.8	25
96	Rediscovering MIF: New Tricks for an Old Cytokine. Trends in Immunology, 2019, 40, 447-462.	6.8	59
97	OP0246â€ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FRO DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .	М	0
98	OP0020â€LESS IS MORE: ANA-LYSING THE IMPACT OF REPEATED ANTINUCLEAR ANTIBODY TESTING. , 2019, , .		0
99	OP0330â€#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0
100	THU0253â€EFFECT OF GLUCOCORTICOIDS ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0
101	AB0539â€TEN YEARS OF THE MONASH LUPUS CLINIC: INSIGHT INTO THE CHARACTERISTICS AND OUTCOMES SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN AUSTRALIA. , 2019, , .	OF	0
102	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	2.7	15
103	Machine learning applied to wholeâ€blood RNAâ€sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. Clinical and Translational Immunology, 2019, 8, e01093.	3.8	43
104	A potential association between ILâ€3 and type I and III interferons in systemic lupus erythematosus. Clinical and Translational Immunology, 2019, 8, e01097.	3.8	15
105	Systemic Glucocorticoid Therapy for SLE. , 2019, , 661-672.		0
106	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	1.9	24
107	Response to: â€~Comment on: â€~Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg. Annals of the Rheumatic Diseases, 2019, 78, e122-e122.	0.9	4
108	Serum soluble Fas and Fas ligand (FasL) in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 254-256.	0.8	1

#	Article	IF	CITATIONS
109	Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Scientific Reports, 2018, 8, 3268.	3.3	23
110	Acceptability of optâ€out consent in a hospital patient population. Internal Medicine Journal, 2018, 48, 84-87.	0.8	12
111	Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab. Annals of the Rheumatic Diseases, 2018, 77, 706-713.	0.9	64
112	Medical student psychological distress and academic performance. Medical Teacher, 2018, 40, 1257-1263.	1.8	43
113	Stress and the onset of SLE. Nature Reviews Rheumatology, 2018, 14, 127-128.	8.0	15
114	Identification of a novel autoantibody against self-vimentin specific in secondary Sjögren's syndrome. Arthritis Research and Therapy, 2018, 20, 30.	3.5	7
115	Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus, 2018, 27, 501-506.	1.6	57
116	Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000277.	2.7	10
117	Analysis of serum macrophage migration inhibitory factor and Dâ€dopachrome tautomerase in systemic sclerosis. Clinical and Translational Immunology, 2018, 7, e1042.	3.8	14
118	Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. Lupus, 2018, 27, 2029-2040.	1.6	16
119	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PLoS ONE, 2018, 13, e0199003.	2.5	46
120	Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1250.	4.8	89
121	Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay. Theranostics, 2018, 8, 846-859.	10.0	12
122	GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenance. Development (Cambridge), 2018, 145, .	2.5	25
123	Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis. International Immunopharmacology, 2018, 61, 140-149.	3.8	34
124	Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nature Communications, 2018, 9, 2223.	12.8	142
125	MIF antagonism restores corticosteroid sensitivity in a murine model of severe asthma. , 2018, ,		0
126	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268

#	Article	IF	CITATIONS
127	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. Journal of Rheumatology, 2017, 44, 271-278.	2.0	6
128	Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Seminars in Arthritis and Rheumatism, 2017, 46, 798-803.	3.4	18
129	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Research and Therapy, 2017, 19, 62.	3.5	100
130	Validation of the Lupus Impact Tracker in an Australian patient cohort. Lupus, 2017, 26, 98-105.	1.6	17
131	Treat to target, remission and low disease activity in SLE. Best Practice and Research in Clinical Rheumatology, 2017, 31, 342-350.	3.3	24
132	Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?. Lupus Science and Medicine, 2017, 4, e000212.	2.7	24
133	Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. Scientific Reports, 2017, 7, 16615.	3.3	38
134	The Australian Lupus Registry and Biobank: a timely initiative. Medical Journal of Australia, 2017, 206, 194-195.	1.7	25
135	Editorial: Focus on Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 400.	4.8	Ο
136	lt hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology, 2016, 56, kew406.	1.9	43
137	Independent association of glucocorticoids with damage accrual in SLE. Lupus Science and Medicine, 2016, 3, e000157.	2.7	77
138	Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. Autophagy, 2016, 12, 907-916.	9.1	83
139	Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nature Medicine, 2016, 22, 991-993.	30.7	457
140	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 2016, 18, 260.	3.5	44
141	Remission in SLE — are we there yet?. Nature Reviews Rheumatology, 2016, 12, 696-698.	8.0	11
142	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Scientific Reports, 2016, 6, 34604.	3.3	81
143	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Scientific Reports, 2016, 6, 29909.	3.3	35
144	Glucocorticoid-Induced Leucine Zipper Protein Controls Macropinocytosis in Dendritic Cells. Journal of Immunology, 2016, 197, 4247-4256.	0.8	16

#	Article	IF	CITATIONS
145	Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 739-747.	0.9	36
146	New answers to old problems. Nature Reviews Rheumatology, 2016, 12, 73-74.	8.0	3
147	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases, 2016, 75, 1615-1621.	0.9	421
148	Brief Report: Interleukinâ€38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 3219-3225.	5.6	102
149	Disseminated Enteroviral Infection Associated with Obinutuzumab. Emerging Infectious Diseases, 2015, 21, 1661-1663.	4.3	21
150	MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus. Frontiers in Immunology, 2015, 6, 577.	4.8	65
151	Glucocorticoidâ€Induced Leucine Zipper Governs the Therapeutic Potential of Mesenchymal Stem Cells by Inducing a Switch From Pathogenic to Regulatory Th17 Cells in a Mouse Model of Collagenâ€Induced Arthritis. Arthritis and Rheumatology, 2015, 67, 1514-1524.	5.6	40
152	Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine, 2015, 72, 135-145.	3.2	39
153	Successes, challenges and developments in Australian rheumatology. Nature Reviews Rheumatology, 2015, 11, 430-436.	8.0	7
154	GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation. Journal of Autoimmunity, 2015, 61, 73-80.	6.5	47
155	Bclâ€2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupusâ€Prone Mice and Dampen Interferonâ€Î± Production. Arthritis and Rheumatology, 2015, 67, 797-808.	5.6	43
156	Manipulation of B-cell responses with histone deacetylase inhibitors. Nature Communications, 2015, 6, 6838.	12.8	73
157	Optimizing the use of existing therapies in lupus. International Journal of Rheumatic Diseases, 2015, 18, 129-137.	1.9	21
158	The Role and Effects of Glucocorticoid-Induced Leucine Zipper in the Context of Inflammation Resolution. Journal of Immunology, 2015, 194, 4940-4950.	0.8	99
159	Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. Lupus Science and Medicine, 2015, 2, e000105.	2.7	12
160	Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Science and Medicine, 2015, 2, e000064-e000064.	2.7	70
161	Infections and musculoskeletal conditions. Best Practice and Research in Clinical Rheumatology, 2015, 29, 187-188.	3.3	0
162	Remission in SLE: closing in on the target. Annals of the Rheumatic Diseases, 2015, 74, 2103-2106.	0.9	19

#	Article	IF	CITATIONS
163	Vitamin D and systemic lupus erythematosus: continued evolution. International Journal of Rheumatic Diseases, 2015, 18, 242-249.	1.9	33
164	Development of novel treatment strategies for inflammatory diseasesââ,¬â€similarities and divergence between glucocorticoids and GILZ. Frontiers in Pharmacology, 2014, 5, 169.	3.5	38
165	Erratum to â€~Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction' [J Mol Cell Cardiol 69 (2014) 32–42]. Journal of Molecular and Cellular Cardiology, 2014, 75, 198.	1.9	0
166	Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoidâ€induced Leucine Zipper. Arthritis and Rheumatology, 2014, 66, 2059-2070.	5.6	43
167	A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. British Journal of Pharmacology, 2014, 171, 4087-4096.	5.4	58
168	Macrophage migration inhibitory factor. Aids, 2014, 28, 1693-1694.	2.2	0
169	The BAFF/APRIL system in SLE pathogenesis. Nature Reviews Rheumatology, 2014, 10, 365-373.	8.0	338
170	Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. Journal of Molecular and Cellular Cardiology, 2014, 69, 32-42.	1.9	52
171	Endogenous Myeloperoxidase Is a Mediator of Joint Inflammation and Damage in Experimental Arthritis. Arthritis and Rheumatology, 2014, 66, 907-917.	5.6	49
172	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.9	558
173	GILZ: a new link between the hypothalamic pituitary adrenal axis and rheumatoid arthritis?. Immunology and Cell Biology, 2014, 92, 747-751.	2.3	6
174	The need to define treatment goals for systemic lupus erythematosus. Nature Reviews Rheumatology, 2014, 10, 567-571.	8.0	43
175	GILZ: Glitzing up our understanding of the glucocorticoid receptor in psychopathology. Brain Research, 2014, 1574, 60-69.	2.2	25
176	A1.38â€Mesenchymal stem cells induce non-classical IL-10-producing regulatory TH17 cells in arthritis: role of gilz. Annals of the Rheumatic Diseases, 2014, 73, A16.2-A16.	0.9	2
177	A8.11â€gilz-dependent activin a production by MSC inhibits TH17 differentiation. Annals of the Rheumatic Diseases, 2014, 73, A80.2-A80.	0.9	2
178	Annexin A1: potential for glucocorticoid sparing in RA. Nature Reviews Rheumatology, 2013, 9, 595-603.	8.0	73
179	Deficiency of Annexin A1 in CD4+ T Cells Exacerbates T Cell–Dependent Inflammation. Journal of Immunology, 2013, 190, 997-1007.	0.8	61
180	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Annals of the Rheumatic Diseases, 2013, 72, 165-178.	0.9	315

#	Article	IF	CITATIONS
181	Regulation of lung fibroblast activation by annexin A1. Journal of Cellular Physiology, 2013, 228, 476-484.	4.1	50
182	Fibroblasts and synovial immunity. Current Opinion in Pharmacology, 2013, 13, 565-569.	3.5	33
183	Reperfusionâ€induced myocardial dysfunction is prevented by endogenous annexinâ€ <scp>A</scp> 1 and its <scp>N</scp> â€terminalâ€derived peptide <scp>A</scp> câ€ <scp>ANX</scp> â€ <scp>A</scp> 1 _{2â€26British Journal of Pharmacology, 2013, 168, 238-252.}	1 b5. 4	53
184	Genetic variants in the human glucocorticoidâ€induced leucine zipper (<i><scp>GILZ</scp></i>) gene in fertile and infertile men. Andrology, 2013, 1, 451-455.	3.5	5
185	Macrophage Migration Inhibitory Factor Receptor CD74 Mediates Alphavirusâ€Induced Arthritis and Myositis in Murine Models of Alphavirus Infection. Arthritis and Rheumatism, 2013, 65, 2724-2736.	6.7	40
186	Divergent Effects of Endogenous and Exogenous Glucocorticoidâ€Induced Leucine Zipper in Animal Models of Inflammation and Arthritis. Arthritis and Rheumatism, 2013, 65, 1203-1212.	6.7	50
187	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus, 2013, 22, 1425-1430.	1.6	65
188	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus, 2013, 22, 873-884.	1.6	74
189	Focus on systemic lupus erythematosus in Indigenous <scp>A</scp> ustralians: towards a better understanding of autoimmune diseases. Internal Medicine Journal, 2013, 43, 227-234.	0.8	23
190	<scp>A</scp> sian ethnicity in systemic lupus erythematosus: an <scp>A</scp> ustralian perspective. Internal Medicine Journal, 2013, 43, 618-624.	0.8	21
191	GILZ Overexpression Inhibits Endothelial Cell Adhesive Function through Regulation of NF-κB and MAPK Activity. Journal of Immunology, 2013, 191, 424-433.	0.8	57
192	Neutrophil myeloperoxidase regulates T-cellâ^'driven tissue inflammation in mice by inhibiting dendritic cell function. Blood, 2013, 121, 4195-4204.	1.4	124
193	Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Research and Therapy, 2013, 15, R97.	3.5	122
194	Glucocorticoid-Induced Leucine Zipper (GILZ) Regulates Testicular FOXO1 Activity and Spermatogonial Stem Cell (SSC) Function. PLoS ONE, 2013, 8, e59149.	2.5	29
195	Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells. PLoS ONE, 2013, 8, e76206.	2.5	51
196	THU0298â€Consensus Definition of a Low Disease Activity State in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2013, 72, A267.1-A267.	0.9	1
197	A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Research, 2012, 40, 8048-8058.	14.5	167
198	Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement. Lupus, 2012, 21, 632-641.	1.6	7

#	Article	IF	CITATIONS
199	BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunology and Cell Biology, 2012, 90, 293-303.	2.3	79
200	Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. Cellular Immunology, 2012, 272, 293-298.	3.0	20
201	ARA Scientific Posters. Internal Medicine Journal, 2012, 42, 9-35.	0.8	4
202	Targeting the side effects of steroid therapy in autoimmune diseases: the role of GILZ. Discovery Medicine, 2012, 13, 123-33.	0.5	30
203	Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia–reperfusion injury: A predominant role of anti-inflammation. Journal of Molecular and Cellular Cardiology, 2011, 50, 991-999.	1.9	99
204	Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nature Reviews Rheumatology, 2011, 7, 340-348.	8.0	109
205	Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus. Internal Medicine Journal, 2011, 41, 495-498.	0.8	3
206	Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin. Clinical and Experimental Immunology, 2011, 163, 178-188.	2.6	20
207	Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis and Rheumatism, 2011, 63, 960-970.	6.7	84
208	Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12048-12053.	7.1	76
209	Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase. Journal of Immunology, 2011, 186, 4915-4924.	0.8	90
210	Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor α. Arthritis and Rheumatism, 2010, 62, 1017-1025.	6.7	23
211	Glucocorticoidâ€induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis and Rheumatism, 2010, 62, 2651-2661.	6.7	80
212	Macrophage Migration Inhibitory Factor Increases Leukocyte–Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. Journal of Immunology, 2010, 185, 1238-1247.	0.8	89
213	Correction: Macrophage Migration Inhibitory Factor Increases Leukocyte–Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. Journal of Immunology, 2010, 185, 4959-4959.	0.8	0
214	Identification of NURR1 as a Mediator of MIF Signaling During Chronic Arthritis. American Journal of Pathology, 2010, 177, 2366-2378.	3.8	21
215	Annexin-1 Regulates Macrophage IL-6 and TNF via Glucocorticoid-Induced Leucine Zipper. Journal of Immunology, 2009, 183, 1435-1445.	0.8	104
216	Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-γ: Involvement of JNK and MAPK phosphatase-1. Cellular Immunology, 2009, 255, 26-32.	3.0	19

#	Article	IF	CITATIONS
217	Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor. Journal of Inflammation, 2009, 6, 24.	3.4	5
218	Independent roles of Macrophage Migration Inhibitory Factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. Microcirculation, 2009, 16, 735-748.	1.8	22
219	Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis. Clinica Chimica Acta, 2009, 399, 1-7.	1.1	102
220	The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clinical and Experimental Immunology, 2008, 152, 345-353.	2.6	24
221	Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clinical and Experimental Immunology, 2008, 152, 372-380.	2.6	46
222	276 Annexin-1 regulates cytokines and dexamethasone sensitivity via glucocorticoid-induced leucine zipper. Cytokine, 2008, 43, 309.	3.2	0
223	MAPK phosphatases as novel targets for rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 2008, 12, 795-808.	3.4	35
224	Mechanisms of Disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nature Clinical Practice Rheumatology, 2008, 4, 98-105.	3.2	72
225	Inflammatory Arthritis. , 2007, , 229-255.		0
226	Macrophage Migration Inhibitory Factor: A Therapeutic Target Across Inflammatory Diseases. Inflammation and Allergy: Drug Targets, 2007, 6, 183-190.	1.8	79
227	Effects of glucocorticoids on inflammation and arthritis. Current Opinion in Rheumatology, 2007, 19, 302-307.	4.3	29
228	Evidence for the role of CD74 in innate immunity, arthritis, and the action of migration inhibitory factor. Arthritis Research and Therapy, 2007, 9, P25.	3.5	1
229	Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R132.	3.5	67
230	Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Letters, 2006, 580, 974-981.	2.8	93
231	MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Reviews Drug Discovery, 2006, 5, 399-411.	46.4	317
232	ILâ€18 is redundant in Tâ€cell responses and in joint inflammation in antigenâ€induced arthritis. Immunology and Cell Biology, 2006, 84, 166-173.	2.3	17
233	The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wiener Medizinische Wochenschrift, 2006, 156, 11-18.	1.1	38
234	Regulation of Annexin I in Rheumatoid Synovial Cells by Glucocorticoids and Interleukin-1. Mediators of Inflammation, 2006, 2006, 1-6.	3.0	17

#	Article	IF	CITATIONS
235	The Anti-Inflammatory Role of Annexin-1 in Arthritis. Current Rheumatology Reviews, 2006, 2, 325-331.	0.8	1
236	Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2. Journal of Immunology, 2006, 177, 8072-8079.	0.8	207
237	Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology, 2006, 45, 937-943.	1.9	57
238	Regulation of IL-1 and TNF Receptor Expression and Function by Endogenous Macrophage Migration Inhibitory Factor. Journal of Immunology, 2006, 177, 4818-4825.	0.8	76
239	Annexin 1 Negatively Regulates IL-6 Expression via Effects on p38 MAPK and MAPK Phosphatase-1. Journal of Immunology, 2006, 177, 8148-8153.	0.8	44
240	Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/lpr Mice. Journal of Immunology, 2006, 177, 5687-5696.	0.8	130
241	New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Internal Medicine Journal, 2005, 35, 419-426.	0.8	105
242	Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis and Rheumatism, 2005, 52, 1325-1332.	6.7	54
243	Macrophage migration inhibitory factor in rheumatoid arthritis. Frontiers in Bioscience - Landmark, 2005, 10, 12.	3.0	65
244	Modulation of inflammation and response to dexamethasone by Annexin 1 in antigenâ€induced arthritis. Arthritis and Rheumatism, 2004, 50, 976-984.	6.7	149
245	Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: Up-regulation by interleukin-1? and glucocorticoids. Arthritis and Rheumatism, 2004, 50, 3118-3128.	6.7	69
246	Reduction in Arthritis Severity and Modulation of Immune Function in Tissue Factor Cytoplasmic Domain Mutant Mice. American Journal of Pathology, 2004, 164, 109-117.	3.8	32
247	The Cytoplasmic Domain of Tissue Factor Contributes to Leukocyte Recruitment and Death in Endotoxemia. American Journal of Pathology, 2004, 165, 331-340.	3.8	44
248	Macrophage migration inhibitory factor in systemic lupus erythematosus. Journal of Rheumatology, 2004, 31, 268-73.	2.0	104
249	Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. Journal of Rheumatology, 2004, 31, 1038-43.	2.0	49
250	Macrophage migration inhibitory factor: An emerging therapeutic target in rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 291-299.	6.7	67
251	Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis and Rheumatism, 2003, 48, 103-109.	6.7	109
252	Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis and Rheumatism, 2003, 48, 1881-1889.	6.7	103

#	Article	IF	CITATIONS
253	Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?. Immunology and Cell Biology, 2003, 81, 367-373.	2.3	21
254	Title is missing!. Arthritis Research, 2003, 5, 127.	2.0	0
255	Therapeutic opportunities for antagonism of macrophage migration inhibitory factor. Expert Opinion on Therapeutic Patents, 2003, 13, 1189-1212.	5.0	2
256	Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. British Journal of Rheumatology, 2003, 42, 390-391.	2.3	8
257	Lower level of synovial fluid interferon-Â in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. British Journal of Rheumatology, 2003, 43, 249-250.	2.3	8
258	Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. British Journal of Rheumatology, 2002, 41, 558-562.	2.3	108
259	Rheumatology. Medical Journal of Australia, 2002, 176, 41-41.	1.7	Ο
260	Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clinical and Experimental Immunology, 2001, 123, 309-314.	2.6	117
261	Hypothalamic–pituitary–adrenal axis regulation of inflammation in rheumatoid arthritis. Immunology and Cell Biology, 2001, 79, 395-399.	2.3	37
262	Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis and Rheumatism, 2001, 44, 1273-1280.	6.7	104
263	Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. , 2001, 44, 1273.		2
264	Corticosteroids in the treatment of rheumatologic diseases. Current Opinion in Rheumatology, 2000, 12, 171-177.	4.3	14
265	Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis and Rheumatism, 2000, 43, 827.	6.7	88
266	Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes. Arthritis and Rheumatism, 2000, 43, 2537-2542.	6.7	17
267	Endogenous glucocorticoids modulate experimental anti-glomerular basement membrane glomerulonephritis. Clinical and Experimental Immunology, 2000, 119, 161-168.	2.6	10
268	Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes. Mediators of Inflammation, 2000, 9, 125-132.	3.0	16
269	Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology, 1999, 38, 59-65.	1.9	35
270	Glucocorticoid regulation of inflammation: The plot thickens. Inflammation Research, 1999, 48, 557-560.	4.0	42

#	Article	IF	CITATIONS
271	Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis and Rheumatism, 1999, 42, 1538-1544.	6.7	82
272	Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis and Rheumatism, 1999, 42, 1601-1608.	6.7	285
273	Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Australian and New Zealand Journal of Medicine, 1998, 28, 18-22.	0.5	34
274	Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis and Rheumatism, 1998, 41, 910-917.	6.7	144
275	Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus. Clinical Rheumatology, 1998, 17, 271-276.	2.2	6
276	Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1. Clinical and Experimental Immunology, 1998, 111, 117-122.	2.6	32
277	Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clinical and Experimental Immunology, 1998, 112, 383-388.	2.6	33
278	Body composition in systemic lupus erythematosus. Rheumatology, 1998, 37, 514-519.	1.9	48
279	Corticosteroids in the treatment of rheumatologic diseases. Current Opinion in Rheumatology, 1998, 10, 179-183.	4.3	11
280	Methotrexate use in systemic lupus erythematosus. Lupus, 1997, 6, 385-389.	1.6	27
281	Corticosteroids in the treatment of rheumatologic diseases. Current Opinion in Rheumatology, 1997, 9, 200-205.	4.3	4
282	Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clinical and Experimental Immunology, 1997, 107, 248-253.	2.6	48
283	Antiinflammatory effect of lipocortin 1 in experimental arthritis. Inflammation, 1997, 21, 583-596.	3.8	61
284	Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor. Inflammation, 1997, 21, 299-311.	3.8	25
285	Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. Journal of Rheumatology, 1997, 24, 1758-64.	2.0	17
286	Advances in the understanding of neuroendocrine function in rheumatic disease. Australian and New Zealand Journal of Medicine, 1996, 26, 543-551.	0.5	4
287	Differential distribution of annexins-I, -II, -IV, and -VI in synovium Annals of the Rheumatic Diseases, 1995, 54, 841-845.	0.9	41
288	Detection of Intracellular Lipocortin 1 in Human Leukocyte Subsets. Clinical Immunology and Immunopathology, 1995, 76, 195-202.	2.0	57

#	Article	IF	CITATIONS
289	Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritistolerance of therapy Annals of the Rheumatic Diseases, 1994, 53, 703-703.	0.9	2
290	Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus. Lupus, 1994, 3, 187-191.	1.6	53
291	Impaired Glucocorticoid Induction of Mononuclear Leukocyte Lipocortin-1 in Rheumatoid Arthritis. Arthritis and Rheumatism, 1994, 37, 207-211.	6.7	38
292	Abnormal hypothalamic—pituitary—adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis and Rheumatism, 1994, 37, 1132-1137.	6.7	64
293	Single anticardiolipin measurement in the routine management of patients with systemic lupus erythematosus. Journal of Rheumatology, 1994, 21, 91-3.	2.0	6
294	BSR Poster Session a. Rheumatology, 1993, 32, 3-88.	1.9	0
295	SCLEROTHERAPY AS TREATMENT OF RECURRENT BLEEDING FROM UPPER GASTROINTESTINAL TELANGIECTASIA IN CREST SYNDROME. Rheumatology, 1993, 32, 760-761.	1.9	11
296	IDIOPATHIC POLYMYOSITIS COMPLICATED BY ARTHRITIS AND MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS: CASE REPORT AND REVIEW OF THE LITERATURE. Rheumatology, 1993, 32, 929-931.	1.9	22
297	GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS—MEDIATORS AND MECHANISMS. Rheumatology, 1993, 32, 816-819.	1.9	9
298	Lack of involvement of lipocortin 1 in dexamethasone suppression of IL-1 release. Mediators of Inflammation, 1993, 2, 49-52.	3.0	4
299	Connective tissue disease: an approach. Australian Family Physician, 1993, 22, 2107-11.	0.5	0
300	Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis Annals of the Rheumatic Diseases, 1992, 51, 1318-1321.	0.9	59
301	Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. Journal of Rheumatology, 1992, 19, 704-8.	2.0	42
302	Medical problems in joint replacement patients: a retrospective study of 243 total hip arthroplasties. Medical Journal of Australia, 1990, 152, 408-413.	1.7	6
303	Regulation of Glucocorticoid Sensitivity by Macrophage Migration Inhibitory Factor. , 0, , 145-161.		0
304	Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients. Modern Rheumatology, 0, , .	1.8	0